Organisation paid for research Program year 2025 Source: CMS Open Payments

Spectrum Health System

Neither a doctor nor a teaching hospital

Research payments

$2,570,571

511 payments

Through program year 2025, Spectrum Health System is reported as receiving $2,570,571 in research payments, across 511 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$189,925	68
2024	Research	$346,197	39
2023	Research	$380,156	108
2022	Research	$381,294	111
2021	Research	$564,094	55
2020	Research	$507,933	89
2019	Research	$200,972	41

Breakdown

Who paid Research payments · program years 2019–2025

Boston Scientific Corporation $487,272 26 payments
Stryker Corporation $387,356 41 payments
E.R. Squibb & Sons, L.L.C. $285,063 4 payments
Roche TCRC, Inc. $220,519 15 payments
Ethicon Endo-Surgery Inc. $184,053 28 payments
United Therapeutics Corporation $152,946 50 payments
H. Lundbeck A S $131,989 36 payments
Genentech, Inc. $126,317 44 payments
AveXis $95,316 24 payments
Imperative Care, INc $56,111 14 payments

Studies the money was for Research payments · program years 2019–2025

Reprise IV $483,522 24 payments
Evolve $292,737 26 payments
A Randomized, Double-blind, Placebo-controlled Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Septal Reduction Therapy $232,552 1 payment
Phase II Study in Early Stage Parkinson S Disease Patients $202,890 15 payments
A Prospective, Single-Arm, Multi-Center Study of the ECHELON EndopathTM Staple Line Reinforcement Device in Bariatric and Lung Resection Procedures $136,845 19 payments
Long Term Follow Up Study of Patients With Spinal Muscular Atrophy Receiving Risdiplam Treatment $80,869 20 payments
A Global Study of A Single, One-Time Dose of Avxs-101 Delivered to Infants With Genetically Diagnosed and Pre-Symptomatic Spinal Muscular Atrophy With Multiple Copies of Smn2 $79,213 22 payments
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine (Prospect-2) $73,385 23 payments
An Open-Label Extension Study of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease $64,899 15 payments
Tenecteplase in Stroke Patients Between 4 5 and 24 Hours $63,077 24 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.